by Cedar Tree Healthcare
A screening test for the presence of Epstein-Barr virus DNA to find early stage nasopharyngeal cancer.
EBV DNA Quantitation has been found to be useful for the monitoring of treatment response and prognostication of EBV associated malignancies, such as nasopharyngeal cancer (NPC), infectious mononucleosis (IM), lymphoproliferative disease and lymphoma.
This is a blood test monitoring for tumour DNA circulating in the bloodstream – also referred to as a “liquid biopsy”. It tests for the presence of DNA in the blood and is a recognised way to screen for early nasopharyngeal cancer in high-risk individuals without symptoms. Early detection can be lifesaving because it allows early stage treatment. Radiation therapy is often used as treatment for nasopharyngeal cancer.
In Asia, nasopharyngeal cancer accounts for more than 80% of all cases in the world, with the highest prevalence in Singapore and Malaysia.